secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2026-09-14T20:10:18+00:00
Accession:  0001193125-26-390577
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna cuts workforce 46%, plans Phase 2a trial for SION-451+SION-2222
----------------------------------------------------------------------

- Board approved restructuring cutting ~46% of workforce, retaining core clinical capabilities for SION-451 and SION-2222.
- Estimated restructuring charges of ~$6.4M, including $5.3M severance and $0.7M contract close-out for SION-719.
- Chief Business Officer Caroline Stark Beer terminated without cause effective Sept 15, 2026; severance benefits approved.
- Stock options repriced to closing price on Sept 17, 2026 for retained employees; original price reinstated if exercised before 18 months.
- Plans to advance SION-451+SION-2222 into Phase 2a proof-of-concept trial initiating Q1 2027; cash runway extended into H2 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/0001193125-26-390577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000119312526390577/d148638d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-390577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer